CURIS INC
CRIS evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $2.7M
- Lead Asset:
- CA-170 (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for CRIS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRIS
Curis Inc. is a clinical-stage biotechnology company developing emavusertib, an oral IRAK4/FLT3 inhibitor for blood cancers, but faces severe financial constraints that raise substantial doubt about its ability to continue as a going concern.
Key risk: Imminent cash depletion
BioSniper Score
Based on 4 of 6 signals
Market Cap
$2.7M
Cash Runway
—
Lead Asset
CA-170 (Phase 2/Phase 3)
Next Catalyst
Patent_Expiry · Dec 15, 2028Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 5 clinical trials · 1 catalyst for CURIS INC.
Curis Inc. is a clinical-stage biotechnology company developing emavusertib, an oral IRAK4/FLT3 inhibitor for blood cancers, but faces severe financial constraints that raise substantial doubt about its ability to continue as a going concern.
- Curis's sole clinical-stage asset is emavusertib (CA-4948), an oral IRAK4/FLT3 inhibitor in Phase 2 for chronic lymphocytic leukemia, relapsed hematologic malignancy, and acute myelogenous leukemia [pipeline].
- Emavusertib has received Orphan Drug Designation from the European Commission (July 2024) and U.S. FDA (December 2024) for primary central nervous system lymphoma (PCNSL) [pipeline].
- As of June 30, 2026, Curis reported cash & equivalents of $5.1M, zero revenue, a net loss of $8.6M, and shareholders' equity of $4.7M [sec].
- The company completed an August 2026 public offering with estimated net proceeds of ~$4.8M, but expects available cash to fund operations only into the fourth quarter of 2026 [sec_mda · as of 2026-08-14].
- Curis has disclosed that it does not have sufficient cash on hand to support current operations beyond 12 months and that these factors raise substantial doubt about its ability to continue as a going concern [sec · filed 2026-08-10].
What works
- Emavusertib has shown positive updated clinical trial results, with a key readout expected in December 2026 [news · published 2026-07-27].
- The drug has received Orphan Drug Designation from both the European Commission and U.S. FDA for PCNSL, which may provide development incentives and market exclusivity [pipeline].
- Curis has engaged with the CHMP on potential Conditional Marketing Authorization in Europe and with the FDA on a potential NDA submission for Accelerated Approval [pipeline].
What to weigh
- Curis has zero revenue and recurring net losses, with a net loss of $8.6M for the six months ended June 30, 2026 [sec].
- Cash and cash equivalents of $5.1M (June 30, 2026) plus ~$4.8M from the August 2026 offering are expected to fund operations only into Q4 2026, and the company states it does not have sufficient cash to support operations beyond 12 months [sec · filed 2026-08-10] [sec_mda · as of 2026-08-14].
- The company has explicitly raised substantial doubt about its ability to continue as a going concern and has warned that if unable to obtain sufficient capital, it may need to dissolve, liquidate, or seek bankruptcy protection [sec · filed 2026-08-10].
- Curis's future depends entirely on the success of emavusertib, and the successful development and commercialization of that drug is described as 'highly uncertain' [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Cash runway is extremely short, only into Q4 2026.
“we expect these available cash resources to fund our existing operations into the fourth quarter of 2026.”
SEC filings · August 10, 2026
The company has raised substantial doubt about its ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”
SEC filings · August 10, 2026
Emavusertib has Orphan Drug Designation from both EC and FDA for PCNSL.
“Orphan Drug Designation by the European Commission (July 2024) and U.S. FDA (December 2024) for PCNSL”
The successful development of emavusertib is highly uncertain.
“The successful development and commercialization of emavusertib is highly uncertain.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2028-12-15 · Patent_Expiry · VISMODEGIB — Patent_Expiry: NDA203388 — Patent expiry for VISMODEGIB; may affect competitive landscape or licensing opportunities, but relevance to Curis's current pipeline is unclear.
Risks & what to watch (4)›
Key risks
- Imminent cash depletion — Cash expected to fund operations only into Q4 2026; no assurance of additional financing [sec · filed 2026-08-10].
- Going concern uncertainty
- Single-asset dependency — All resources focused on emavusertib; its failure would leave no other pipeline candidates [sec_mda · as of 2026-08-14].
- Bankruptcy risk — Company may need to dissolve, liquidate, or seek bankruptcy protection if unable to raise capital [sec · filed 2026-08-10].
What to watch
- December 2026 clinical readout for emavusertib, which is a key catalyst for the stock [news · published 2026-07-24].
- Ability to raise additional financing or enter a collaboration/licensing deal for emavusertib [sec_mda · as of 2026-08-14].
- Regulatory decisions from CHMP on Conditional Marketing Authorization and FDA on Accelerated Approval for emavusertib [pipeline].
- Cash burn rate and whether the company can extend its runway beyond Q4 2026 [sec · filed 2026-08-10].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run CURIS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CURIS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 3.04 · 0% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~793d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 0.7%
- Days to cover
- 0.3
- Shares short
- 262,332
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRIS short interestGovernance
Frequently asked questions
What is the AI investment thesis for CURIS INC?
Curis Inc. is a clinical-stage biotechnology company developing emavusertib, an oral IRAK4/FLT3 inhibitor for blood cancers, but faces severe financial constraints that raise substantial doubt about its ability to continue as a going concern.
What is CURIS INC's lead drug candidate?
CURIS INC's most advanced tracked candidate is CA-170 (Phase 2/Phase 3) for Being evaluated in combination with chemoradiation in non-squamous non-small cell lung cancer (Phase 2b/3 randomized study).
What is CURIS INC's next catalyst?
CURIS INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA203388" — expected December 15, 2028.
Who is the CEO of CURIS INC?
Mr. James E. Dentzer is the chief executive officer of CURIS INC (CRIS).
Where is CURIS INC headquartered?
CURIS INC (CRIS) is headquartered in Lexington, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.